Mayne Pharma Group ( (AU:MYX) ) just unveiled an update.
Mayne Pharma Group Limited has announced that a key condition under the Hart-Scott-Rodino Antitrust Improvements Act for its proposed acquisition by Cosette Pharmaceuticals has been satisfied. The scheme of arrangement, which involves Cosette acquiring all shares in Mayne Pharma, still requires approval from the Foreign Investment Review Board, Mayne Pharma shareholders, and final court approval, with the timeline remaining as previously indicated.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals, particularly in dermatology and women’s health in the United States. The company also provides contract development and manufacturing services globally and has a 40-year history of innovation in oral drug delivery systems.
Average Trading Volume: 791,046
Technical Sentiment Signal: Hold
Current Market Cap: A$568.7M
For an in-depth examination of MYX stock, go to TipRanks’ Stock Analysis page.